Vera Therapeutics (VERA) Other Non-Current Liabilities (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Other Non-Current Liabilities data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (changed N/A YoY), and the FY2025 full-year result was $1.9 million, changed N/A from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $1.9 million, down from $1.9 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $1.9 million in Q4 2025 and bottomed at $286000.0 in Q1 2022.
• The 5-year median for Other Non-Current Liabilities is $286000.0 (2022), against an average of $553666.7.
• The widest annual swing landed in 2022, when Other Non-Current Liabilities tumbled 80.07%; it then grew 0.35% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $286000.0 in 2022, then changed by 0.0% to $286000.0 in 2023, then changed by 0.0% to $286000.0 in 2024, then soared by 570.98% to $1.9 million in 2025, then dropped by 2.87% to $1.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $286000.0 (Q2 2024), per Business Quant data.

Peer Comparison